Browse USP19

Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass membrane protein
Domain PF04969 CS domain
PF00443 Ubiquitin carboxyl-terminal hydrolase
PF01753 MYND finger
Function

Deubiquitinating enzyme that regulates the degradation of various proteins. Deubiquitinates and prevents proteasomal degradation of RNF123 which in turn stimulates CDKN1B ubiquitin-dependent degradation thereby playing a role in cell proliferation. Involved in decreased protein synthesis in atrophying skeletal muscle. Modulates transcription of major myofibrillar proteins. Also involved in turnover of endoplasmic-reticulum-associated degradation (ERAD) substrates. Regulates the stability of BIRC2/c-IAP1 and BIRC3/c-IAP2 by preventing their ubiquitination. Required for cells to mount an appropriate response to hypoxia and rescues HIF1A from degradation in a non-catalytic manner. Plays an important role in 17 beta-estradiol (E2)-inhibited myogenesis. Decreases the levels of ubiquitinated proteins during skeletal muscle formation and acts to repress myogenesis. Exhibits a preference towards 'Lys-63'-linked ubiquitin chains.

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0014706 striated muscle tissue development
GO:0016202 regulation of striated muscle tissue development
GO:0016579 protein deubiquitination
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0031647 regulation of protein stability
GO:0034976 response to endoplasmic reticulum stress
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0036503 ERAD pathway
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0045787 positive regulation of cell cycle
GO:0045843 negative regulation of striated muscle tissue development
GO:0045861 negative regulation of proteolysis
GO:0048634 regulation of muscle organ development
GO:0048635 negative regulation of muscle organ development
GO:0048641 regulation of skeletal muscle tissue development
GO:0048642 negative regulation of skeletal muscle tissue development
GO:0050821 protein stabilization
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0061136 regulation of proteasomal protein catabolic process
GO:0070482 response to oxygen levels
GO:0070646 protein modification by small protein removal
GO:0071108 protein K48-linked deubiquitination
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0090068 positive regulation of cell cycle process
GO:1900037 regulation of cellular response to hypoxia
GO:1901799 negative regulation of proteasomal protein catabolic process
GO:1901861 regulation of muscle tissue development
GO:1901862 negative regulation of muscle tissue development
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903051 negative regulation of proteolysis involved in cellular protein catabolic process
GO:1903362 regulation of cellular protein catabolic process
GO:1903363 negative regulation of cellular protein catabolic process
GO:1904292 regulation of ERAD pathway
Molecular Function GO:0004843 thiol-dependent ubiquitin-specific protease activity
GO:0008234 cysteine-type peptidase activity
GO:0019783 ubiquitin-like protein-specific protease activity
GO:0031072 heat shock protein binding
GO:0031625 ubiquitin protein ligase binding
GO:0036459 thiol-dependent ubiquitinyl hydrolase activity
GO:0044389 ubiquitin-like protein ligase binding
GO:0051879 Hsp90 protein binding
GO:0101005 ubiquitinyl hydrolase activity
GO:1990380 Lys48-specific deubiquitinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between USP19 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of USP19 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.92; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of USP19 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0280.9
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0390.984
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0210.989
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2340.424
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3160.9
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1320.967
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1150.719
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0160.992
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2380.896
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.290.824
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1640.514
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0090.873
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of USP19 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of USP19. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of USP19. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by USP19.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of USP19. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of USP19 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between USP19 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUSP19
Nameubiquitin specific peptidase 19
Aliases KIAA0891; ZMYND9; ubiquitin specific protease 19; deubiquitinating enzyme 19; ubiquitin thioesterase 19; ubi ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting USP19 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.